Clinical Trials on Glabellar Crease

Total 10000 results

ImmunityBio, Inc.

Terminated

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Advanced Triple Negative Breast Cancer

United States
Daiichi Sankyo

Completed

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

HER2-negative Breast Cancer | HER2-low Breast Cancer | Hormone-receptor-positive Breast Cancer

United States
Case Comprehensive Cancer Center

Completed

Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

Metastatic Triple Negative Breast Cancer

United States
Miguel Martín Jiménez
UNC Lineberger Comprehensive Cancer Center; Hospital Universitario Ramon y... and other collaborators

Active, not recruiting

Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer

Breast Cancer | Breast Cancer Stage II-III

Spain
Texas Tech University Health Sciences Center, El...

Suspended

Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile

Metastatic Triple-Negative Breast Cancer

United States
Instituto Nacional de Cancer, Brazil
Dana-Farber Cancer Institute

Completed

Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer With CAP Regimen (CAPneo)

Triple Negative Breast Cancer Patients
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
University of Florida

Completed

Improving Lactation Success in Mothers of Critically Infants

Breast Pumping

United States
Prescient Therapeutics, Ltd.
National Cancer Institute (NCI)

Terminated

PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative | Breast Adenocarcinoma

United States
Emory University
National Cancer Institute (NCI)

Recruiting

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
Yuan Yuan
Gateway for Cancer Research; Agenus Inc.

Recruiting

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
Gordon Mills, MD, PhD
AstraZeneca; Oregon Health and Science University

Terminated

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
Merrimack Pharmaceuticals
Sanofi

Completed

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

ER Positive, Her2 Negative Breast Cancer Patients | Triple Negative Breast Cancer Patients

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Active, not recruiting

Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness) (PTW)

Stage 0 Breast Cancer | Cancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Early-Stage Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer

United States
Alison Stopeck

Recruiting

Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | TNBC, Triple Negative Breast Cancer | Locally Advanced Breast Cancer | Neoadjuvant Chemotherapy

United States
City of Hope Medical Center
National Cancer Institute (NCI); Imugene Limited

Active, not recruiting

CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer

Breast Cancer Stage IV | Triple -Negative Breast Cancer

China
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | TNBC - Triple-Negative Breast Cancer

United States
Institute of Cancer Research, United Kingdom
AstraZeneca

Recruiting

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer (PHOENIX)

Breast Neoplasm | HRD | Triple Negative Breast Cancer (TNBC)

United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2 Positive Breast Carcinoma

United States
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

Metastatic Breast Cancer | Metastatic Triple Negative Breast Cancer

Japan, Belgium, France, Netherlands
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
University of Arizona
National Cancer Institute (NCI)

Completed

Diindolylmethane in Treating Patients With Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer

United States
Robert H. Lurie Cancer Center
National Cancer Institute (NCI)

Withdrawn

Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Amgen

Completed

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Breast Cancer | Invasive Breast Carcinoma | Invasive Ductal Breast Carcinoma | Ductal Carcinoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Terminated

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer

Triple Negative Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Estrogen Receptor Negative Breast Cancer

United States
University of Southern California
National Cancer Institute (NCI); California Breast Cancer Research Program

Completed

Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Ductal Breast Carcinoma in Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Lobular Breast Carcinoma in Situ

United States
OHSU Knight Cancer Institute
Eli Lilly and Company; GlaxoSmithKline; Oregon Health and Science University

Completed

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic... and other conditions

United States
Institut Cancerologie de l'Ouest

Recruiting

Assessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients (EXIGENCE)

Metastatic Breast Cancer

France
Dr. Tabassum Wadasadawala

Recruiting

Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy (CONCERT)

Invasive Breast Cancer | Stage IIB Breast Cancer | Stage III Breast Cancer

India
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy

Breast Cancer Invasive
Adrienne G. Waks
Gilead Sciences

Active, not recruiting

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Breast Cancer Female | Breast Cancer Metastatic | Her 2 Positive Breast Cancer

United States
Medical College of Wisconsin

Active, not recruiting

Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (CemiHALT)

Invasive Breast Cancer

United States
Organon and Co
Institute for Applied Economics and Health Research Aps

Completed

Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021).

Male Breast Cancer
Dompé Farmaceutici S.p.A
PRA Health Sciences

Completed

A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer (FRIDA)

Metastatic Breast Cancer

United States, Spain, Belgium, Italy, France, Czechia, Poland
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

India
German Breast Group
Pfizer

Completed

Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients (MALE)

Male Breast Cancer

Germany
Salah Azaïz Cancer Institute

Unknown

Understanding Male Breast Cancer: Salah Azaïz Cancer Institute Experience

Male Breast Cancer

Tunisia
University of Nebraska
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone... and other conditions

United States
Wake Forest University Health Sciences

Active, not recruiting

Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial (STEPS-BC)

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Breast Carcinoma | Breast Inflammatory Carcinoma | Locally Recurrent Breast Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IIIC Breast Cancer | HER2/Neu Negative | Stage III Breast Cancer | Postmenopausal | Estrogen Receptor Status

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Acupuncture in Treating Women With Stage I, Stage II, or Stage III Breast Cancer With Aromatase Inhibitor-Related Joint Pain

Breast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP

Breast Cancer | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | Early-stage Breast Cancer
Institut du Cancer de Montpellier - Val d'Aurelle

Active, not recruiting

Observational Study of Intra-operative Partial Irradiation of Invasive Ductal Breast Carcinomas With a Good Prognosis (INTRA-OBS)

Invasive Breast Cancer | Breast-conserving Surgery

France
Irada Ibrahim-zada

Active, not recruiting

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Breast Cancer | Breast Carcinoma | HER2-negative Breast Cancer | Node-negative Breast Cancer

United States
MedSIR
AstraZeneca; Daiichi Sankyo, Inc.

Completed

Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status (RosHER)

Metastatic Breast Cancer | Early Breast Cancer | Locally Advanced Breast Cancer

Spain
University of Alabama at Birmingham
National Cancer Institute (NCI)

Terminated

A Quality of Life Intervention for Young African American Breast Cancer Survivors in Treatment

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Ohio State University Comprehensive Cancer Center

Completed

Health Coaching-Based Navigation at the Conclusion of Treatment for the Support of Black Breast Cancer Survivors

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Azienda Ospedaliero-Universitaria Careggi

Not yet recruiting

Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy (HELP)

Radiation Therapy | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer Patients | HR+/HER2- Breast Cancer

Italy
Eisai Inc.

Completed

Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Breast Cancer | Breast Neoplasms | Cancer, Breast | Breast Cancer Female | Estrogen Receptor Positive Tumor | Breast Adenocarcinoma | ER Positive | Estrogen-receptor Positive Breast Cancer

France, United Kingdom, United States

Clinical Trials on Glabellar Crease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations